[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Inovio Pharma (INO)

Inovio Pharma (INO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,328
  • Shares Outstanding, K 82,273
  • Annual Sales, $ 70 K
  • Annual Income, $ -84,950 K
  • EBIT $ -84 M
  • EBITDA $ -81 M
  • 60-Month Beta 1.52
  • Price/Sales 856.90
  • Price/Cash Flow N/A
  • Price/Book 7.75
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.02
  • Most Recent Earnings $-0.28 on 05/13/26
  • Next Earnings Date 08/11/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 181.15% (-165.76%)
  • Historical Volatility 140.15%
  • IV Percentile 33%
  • IV Rank 13.46%
  • IV High 908.26% on 08/07/25
  • IV Low 68.09% on 01/28/26
  • Expected Move (DTE 2) 0.2380 (35.89%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 445
  • Volume Avg (30-Day) 2,328
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 71,032
  • Open Int (30-Day) 66,180
  • Expected Range 0.4251 to 0.9011

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 2
  • High Estimate $-0.23
  • Low Estimate $-0.26
  • Prior Year $-0.61
  • Growth Rate Est. (year over year) +59.02%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5632 +17.74%
on 07/30/26
1.2500 -46.95%
on 07/09/26
-0.5569 (-45.65%)
since 07/02/26
3-Month
0.5632 +17.74%
on 07/30/26
1.7900 -62.96%
on 05/08/26
-0.4769 (-41.83%)
since 05/04/26
52-Week
0.5632 +17.74%
on 07/30/26
2.9789 -77.74%
on 09/09/25
-0.8069 (-54.89%)
since 08/04/25

Most Recent Stories

More News
INOVIO to Report Second Quarter Financial Results on August 12, 2026

PLYMOUTH MEETING, Pa. , Aug. 4, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related...

INO : 0.6631 (-4.84%)
INOVIO Announces Pricing of $20.0 Million Public Offering

PLYMOUTH MEETING, Pa. , July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...

INO : 0.6631 (-4.84%)
INOVIO Announces Proposed Public Offering

PLYMOUTH MEETING, Pa. , July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...

INO : 0.6631 (-4.84%)
Kuehn Law Encourages Investors of Inovio Pharmaceuticals, Inc. to Contact Law Firm

NEW YORK , June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Inovio Pharmaceuticals, Inc. (NASDAQ:...

INO : 0.6631 (-4.84%)
INOVIO to Participate in Upcoming Scientific and Investor Conferences

PLYMOUTH MEETING, Pa. , May 28, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related...

INO : 0.6631 (-4.84%)
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances

Inovio Pharmaceuticals (NASDAQ:INO) shareholders approved all proposals presented at the company’s 2026 annual meeting, including the election of eight directors and the ratification of Ernst & Young...

INO : 0.6631 (-4.84%)
Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

PLYMOUTH MEETING, Pa. , May 21, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related...

INO : 0.6631 (-4.84%)
Inovio: Q1 Earnings Snapshot

Inovio: Q1 Earnings Snapshot

INO : 0.6631 (-4.84%)
INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights

PLYMOUTH MEETING, Pa. , May 13, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related...

INO : 0.6631 (-4.84%)
INOVIO to Participate in Upcoming Scientific Conferences

PLYMOUTH MEETING, Pa. , May 8, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related...

INO : 0.6631 (-4.84%)

Business Summary

Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled...

See More

Key Turning Points

3rd Resistance Point 0.7816
2nd Resistance Point 0.7507
1st Resistance Point 0.7069
Last Price 0.6631
1st Support Level 0.6322
2nd Support Level 0.6013
3rd Support Level 0.5575

See More

52-Week High 2.9789
Fibonacci 61.8% 2.0561
Fibonacci 50% 1.7710
Fibonacci 38.2% 1.4860
Last Price 0.6631
52-Week Low 0.5632

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.